Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Karyopharm Therapeutics Inc. (KPTI) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Karyopharm is a commercial-stage pharmaceutical company listed on the Nasdaq Global Select Market, and its filings detail financial results, financing arrangements and key corporate developments related to its oncology-focused business.
Among the most relevant documents for investors are Form 10-K annual reports and Form 10-Q quarterly reports, which summarize financial performance, risk factors and updates on Karyopharm’s commercial product XPOVIO (selinexor) and its clinical pipeline in multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL). These periodic reports typically discuss revenue from U.S. XPOVIO net product sales and license and royalty revenue from partners, as described in the company’s public communications.
The company also files numerous Form 8-K current reports to describe material events. Recent 8-K filings referenced in the provided information include disclosures of quarterly financial results, strategic financing transactions involving senior secured term loans and 9.00% convertible senior notes due 2028 and 2029, and the issuance of equity and warrants in private placements. Other 8-Ks cover topics such as board changes, workforce reductions and the provision of “cleansing materials” to potential investors during financing discussions.
Investors tracking capital structure and liquidity can review exhibits to these filings, which describe credit and guaranty agreements, note purchase agreements, warrant terms and registration rights agreements. For governance and compensation matters, additional filings may include proxy statements and equity award disclosures, such as inducement grants reported under Nasdaq Listing Rule 5635(c)(4).
On this page, Stock Titan supplements raw EDGAR documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand changes in debt, equity, cash runway expectations, and updates on Karyopharm’s clinical and commercial programs. Real-time updates ensure that new 10-Ks, 10-Qs, 8-Ks and other forms appear as they are filed, while specialized views can surface insider-related forms such as Form 4 when available.
Karyopharm Therapeutics Inc. filed a Form S-8 to register an additional 450,000 shares of common stock under its 2022 Equity Incentive Plan, as amended. The filing incorporates prior Form S-8 registrations for the same plan by reference and makes those shares available for issuance as awards to employees and directors. Exhibits listed include the Restated Certificate, Third Amended and Restated By-Laws, counsel opinion and consent, auditor consent, the amended plan text and a filing fee table; the registration statement is signed by the company’s authorized officers and directors.
Karyopharm Therapeutics (KPTI) reported total revenue of $37.9 million for the quarter and $67.9 million year-to-date, driven primarily by U.S. product sales of XPOVIO (net product revenue of $29.7 million in Q2). The company recorded a net loss of $37.3 million for the quarter and $60.7 million for the six months ended June 30, 2025. Cash and short-term investments totaled approximately $51.7 million at June 30, 2025, while total assets were $104.9 million against $343.8 million of liabilities, resulting in a stockholders' deficit of $238.9 million.
The balance sheet shows near-term funding pressures: convertible 2025 Notes of $24.5 million mature October 15, 2025; a $100.0 million senior secured Term Loan (carrying $95.8 million) matures May 2028; and 2029 Notes (principal $116.0 million, carrying $62.7 million) mature in 2029. Management discloses "substantial doubt" about the company’s ability to continue as a going concern within one year and is evaluating strategic and financing alternatives; the company reduced headcount by ~20% as part of cost management.
Karyopharm Therapeutics reported that it has announced its financial results for the quarter ended June 30, 2025 and will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The Form 8-K states the full press release with details is furnished as Exhibit 99.1 and is incorporated by reference into the report.
The filing clarifies that the information in this report and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 liability or automatic incorporation by reference in other Securities Act or Exchange Act filings. The Form 8-K itself does not include the financial figures in-line; investors must review Exhibit 99.1 for the substantive results.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) filed a Form 8-K on 11-Jul-2025 detailing material liquidity and operational actions.
The company disclosed that it held confidential discussions with new and existing investors to extend its cash runway; however, no financing agreement has been reached. To comply with confidentiality agreements, it published the related investor presentation (the “Cleansing Materials”) as Exhibit 99.1.
The Board is actively evaluating strategic alternatives that could include a merger or sale of the company, in- or out-of-court restructurings, or refinancing of existing debt. Management cautions that there is no assurance any transaction will occur or what terms might apply.
To conserve cash, Karyopharm is implementing a 20 % workforce reduction, with one-time charges expected to be immaterial. The company intends to keep supporting commercial sales of XPOVIO for multiple myeloma and to advance ongoing Phase 3 trials in myelofibrosis and endometrial cancer.
The filing reiterates forward-looking risk factors, including substantial doubt about the company’s ability to continue as a going concern absent additional capital.